Litcius/Paper detail

Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

Elizabeth Needham Waddell, Sandra A. Springer, Lisa A. Marsch, David Farabee, Robert P. Schwartz, Amesika N. Nyaku, Rusty Reeves, Keith Goldfeld, Ryan McDonald, Mia Malone, Anna Cheng, Elizabeth C. Saunders, Laura B. Monico, Jan Gryczynski, Kathleen Bell, Kasey Harding, Sandra Violette, Thomas Groblewski, Wendy Martin, Kasey Talon, Nicole Beckwith, Andrew Suchocki, Randy Torralva, Jennifer P. Wisdom, Joshua D. Lee

2021Journal of Substance Abuse Treatment23 citationsDOIOpen Access PDF

Topics & Concepts

BuprenorphineOpioid use disorderNaltrexoneMedicineRandomized controlled trialRecidivismOpioidOpioid overdosePsychiatryPsychologyInternal medicine(+)-NaloxoneReceptorOpioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPrenatal Substance Exposure Effects
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS) | Litcius